MX2024003537A - Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. - Google Patents
Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.Info
- Publication number
- MX2024003537A MX2024003537A MX2024003537A MX2024003537A MX2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A MX 2024003537 A MX2024003537 A MX 2024003537A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- subject
- treating
- cedazuridine
- decitabine
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 6
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 title abstract 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 title abstract 2
- 229940063170 cedazuridine Drugs 0.000 title abstract 2
- 229960003603 decitabine Drugs 0.000 title abstract 2
- 230000004083 survival effect Effects 0.000 abstract 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 abstract 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 abstract 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 abstract 1
- 229940075628 hypomethylating agent Drugs 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246547P | 2021-09-21 | 2021-09-21 | |
| PCT/US2022/076757 WO2023049731A2 (en) | 2021-09-21 | 2022-09-21 | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003537A true MX2024003537A (es) | 2024-05-03 |
Family
ID=85721229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003537A MX2024003537A (es) | 2021-09-21 | 2022-09-21 | Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000888A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4404940A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024531799A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240064656A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118201622A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022348907B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232623A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003537A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202327625A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023049731A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548303A (ja) | 2020-10-29 | 2023-11-16 | 大塚製薬株式会社 | 癌を処置する為の医薬組成物及びその使用方法 |
| AU2024265282A1 (en) * | 2023-05-02 | 2025-12-18 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708264C (en) * | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| US10683552B2 (en) * | 2014-11-25 | 2020-06-16 | Presidents And Fellows Of Harvard College | Clonal haematopoiesis |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| WO2021113688A1 (en) * | 2019-12-05 | 2021-06-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of myelodysplastic syndrome |
| EP4090335A1 (en) * | 2020-01-17 | 2022-11-23 | Novartis AG | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| LT4069254T (lt) * | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
-
2022
- 2022-09-21 MX MX2024003537A patent/MX2024003537A/es unknown
- 2022-09-21 AU AU2022348907A patent/AU2022348907B2/en active Active
- 2022-09-21 US US18/693,727 patent/US20250000888A1/en active Pending
- 2022-09-21 CN CN202280073476.0A patent/CN118201622A/zh active Pending
- 2022-09-21 EP EP22873816.7A patent/EP4404940A4/en active Pending
- 2022-09-21 CA CA3232623A patent/CA3232623A1/en active Pending
- 2022-09-21 TW TW111135794A patent/TW202327625A/zh unknown
- 2022-09-21 WO PCT/US2022/076757 patent/WO2023049731A2/en not_active Ceased
- 2022-09-21 KR KR1020247010215A patent/KR20240064656A/ko active Pending
- 2022-09-21 JP JP2024517163A patent/JP2024531799A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024531799A (ja) | 2024-08-29 |
| US20250000888A1 (en) | 2025-01-02 |
| AU2022348907B2 (en) | 2026-07-16 |
| WO2023049731A2 (en) | 2023-03-30 |
| AU2022348907A1 (en) | 2024-04-11 |
| WO2023049731A3 (en) | 2023-05-04 |
| TW202327625A (zh) | 2023-07-16 |
| CN118201622A (zh) | 2024-06-14 |
| EP4404940A4 (en) | 2025-07-30 |
| EP4404940A2 (en) | 2024-07-31 |
| CA3232623A1 (en) | 2023-03-30 |
| KR20240064656A (ko) | 2024-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| CL2018003577A1 (es) | Piridina substituida como inhibidor de dnmt1. | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| MX2021015993A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico. | |
| CO6331301A2 (es) | Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa | |
| MX2021004231A (es) | Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos. | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| CR20170406A (es) | Arni variante | |
| MX2017000578A (es) | Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. | |
| CR11687A (es) | Terapia de combinación de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada | |
| MX2015012739A (es) | Composiciones y metodos para tratar la mucopolisacaridosis tipo 1. | |
| ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| MX2017009913A (es) | Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes. | |
| MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
| AR112103A1 (es) | Compuestos para el tratamiento de tnbc | |
| AR093569A1 (es) | Tensioactivos pulmonares reconstituidos | |
| MX2019014330A (es) | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. | |
| MX2021004329A (es) | 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos. | |
| CL2019003743A1 (es) | Formas de dosificación oral y de liberación controlada gastrorresistentes. | |
| CO2022007910A2 (es) | Tratamientos contra el cáncer dirigidos a las células madre cancerosas | |
| MX2017005419A (es) | Tratamiento o prevencion de anemia en mamiferos no humanos preñados. | |
| WO2023049731A3 (en) | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine | |
| MX2023006937A (es) | Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos. | |
| CL2024000114A1 (es) | Compuestos terapéuticos y procedimientos. |